Safety and Efficacy of Liraglutide in Parkinson's Disease

Part of paid clinical trials in Los Angeles, California.

Sponsor
Cedars-Sinai Medical Center
Study ID
NCT02953665
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
25 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
  • Placebo — DRUG
    Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg

Study Details

The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).

Key Dates

Start date
Apr 3, 2017
Status verified
Mar 2024
Primary completion
Aug 3, 2022
Completion
Aug 3, 2022

Study Design

Enrollment
63 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Liraglutide
    Liraglutide 6 mg/ml (Novo Nordisk A/S) will be self-administered subcutaneously once daily at a maximum dose of 1.8 mg after a 2 week titration schedule.
  • Placebo Comparator: Placebo
    Placebo will be self-administered subcutaneously once daily according to the same schedule.

Primary Outcome Measure

Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period [ Time Frame: From Baseline (Week 0) to end of Maintenance Period (up to 54 weeks) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cedars Sinai Medical CenterLos AngelesCalifornia90048-

Find similar trials in Los Angeles, CA

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
Cedars Sinai Medical Center· Los Angeles, CA

Related Studies